Recent Updates
Recently added Catalysts
ANGO Positive Sentiment

AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Key Takeaway: AngioDynamics announced the grant of inducement awards to Eric Honroth, who will become the Chief Executive Officer on November 2, 2026. This decision reflects the company's commitment to leadership and innovation in medical technology. The company aims to enhance cancer treatment options and restore healthy blood flow.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of Eric Honroth as CEO
  • Inducement awards granted to new leadership
  • Focus on improving patient quality of life

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
High dilution risk
Lead asset
RF ablation
Phase 2 · Non Small Cell Lung Cancer

Full Press Release Details

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the grant of inducement awards to Eric Honroth in connection with his appointment as Chief Executive Officer of the Company effective as of November 2, 2026. On November 2, 2026 (the “Grant Date”), as an inducement

Frequently Asked Questions

Who is the new CEO of AngioDynamics?

Eric Honroth has been appointed as the new CEO.

When will Eric Honroth start as CEO?

He will officially start on November 2, 2026.

What are inducement awards?

Inducement awards are grants given to attract new leadership.

What is AngioDynamics focused on?

The company focuses on restoring blood flow and cancer treatment.

Last updated: Nov 6, 2026